Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 154.98M P/E - EPS this Y 85.00% Ern Qtrly Grth -
Income -36.85M Forward P/E -0.02 EPS next Y - 50D Avg Chg -
Sales 1M PEG - EPS past 5Y - 200D Avg Chg 25.00%
Dividend N/A Price/Book 2.50 EPS next 5Y - 52W High Chg -18.00%
Recommedations 1.40 Quick Ratio 5.78 Shares Outstanding 153.85M 52W Low Chg 151.00%
Insider Own 1.08% ROA -23.86% Shares Float 484.69M Beta 0.98
Inst Own 65.49% ROE -48.47% Shares Shorted/Prior 4.54M/4.54M Price 1.24
Gross Margin 150.90% Profit Margin - Avg. Volume 1,930,119 Target Price 7.23
Oper. Margin -3,790.40% Earnings Date Aug 13 Volume 485,900 Change -8.15%
About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Mereo BioPharma Group plc News
11/14/24 Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
11/12/24 Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/16/24 Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds?
09/18/24 Mereo BioPharma Group plc (MREO): A Bull Case Theory
09/12/24 Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
08/13/24 Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
06/15/24 Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount
06/14/24 Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
06/12/24 Ultragenyx (RARE) Posts New Data From Bone Disease Study
06/12/24 Ultragenyx, Mereo drug reduces fractures in bone disorder study
06/11/24 Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
05/30/24 Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
05/15/24 Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/12/24 MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
04/03/24 Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
03/27/24 Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results
03/27/24 Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
03/05/24 Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
02/16/24 Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
02/16/24 15 Top Performing European Stocks So Far in 2024
MREO Chatroom

User Image WonderfulMongoose Posted - 14 hours ago

$MREO last week cleared out a lot of weak retail shareholders. We should reclaim 4 soon.

User Image LDT79 Posted - 15 hours ago

$MREO #AATD market projected to grow to $6B by 2031 - huge opportunity to bring an oral molecule to market for Mereo Key players: - Takeda - Kamada Pharmaceuticals - Grifols - CSL - Baxalta - pH Pharma Co - Mereo Biopharma - Novo Nordisk - Arrowhead Pharmaceuticals

User Image CrispDry Posted - 19 hours ago

$MREO $RARE rare is winning between the two

User Image LDT79 Posted - 20 hours ago

$MREO traders, please go fuck yourself alteady

User Image PLATINUM_TRADES Posted - 1 day ago

$MREO beaten down finally a good day and should be even better with tomorrow🏆🏆🏆🏆

User Image halpy518 Posted - 1 day ago

$MREO sell the company. PLEASE

User Image cheetohottaki Posted - 1 day ago

$MREO so I'll just put this out there, for me the best fireside chat I've heard to date and EXTREMELY positive and enthusiatic

User Image cheetohottaki Posted - 1 day ago

$MREO so stealing this from X but man this is encouraging, a true collaboration where both stakeholders work together which is key to success

User Image ScottyDoesntKnowMeSon Posted - 1 day ago

$MREO

User Image davedtire Posted - 1 day ago

$MREO

User Image davedtire Posted - 1 day ago

$mreo https://x.com/semodough/status/1858910610529894608?s=12&t=YEJOuteXsdU9zZ7HW8_OFw

User Image EddieH2020 Posted - 1 day ago

$MREO Why the massive price drop? Cc: @CEOofstocks

User Image cheetohottaki Posted - 1 day ago

$MREO Just listened to call, 80 million in cash so no worries there as that can sustain them through all potential catalyst in to 2027, still deep in discussions for partner funding phase 3 aatd expected to have resolved by eoy, DSK seemed very confident and mentioned both assets with revenue opportunity in billion range for each, so pretty damn exciting and really nothing has changed, she did mention first interim was going to be a very high bar to meet so imo if it does hit lookout for a huge rally

User Image brd03 Posted - 1 day ago

$MREO …dsk’s response regarding setrusumab… https://x.com/ushouldbuythis/status/1858900127752257584?s=12

User Image Locke1 Posted - 1 day ago

$MREO

User Image ScottyDoesntKnowMeSon Posted - 1 day ago

$MREO let’s go Denise. I guess. I’m sure this will just be a repeat of what she’s consistently said. “We’re in discussions, blah blah, something similar to deal with RARE, blah blah” Say something good please. Be bold.

User Image Elvira007 Posted - 2 days ago

$MREO No one and I mean NO ONE wants to see CEO DSK trying to launch Setrusumab for OI in Europe even if its an easy drug to launch with a small sales force. Just give it to $RARE, they already have the salesforce and contacts in place. Why train a new team and screw your partners over. Let them have it, take a 20% royalty (with a big upfront)...Its that fucking easy. Partner out AATD or sell it outright and then go back to looking for new assets to develop and partner again to big pharma....It worked for Ligand. Stock was $10. peaked at $270....They had 20 employees at the time

User Image Elvira007 Posted - 2 days ago

$MREO @cheetohottaki Ultragenyx not on board whatsoever. It's Rubric "inActivists". They are the ones allowing Denise to continue this total shit show of a performance... AATD starting to look like the TIGIT fuckup a few years back...

User Image tic2tape Posted - 2 days ago

$MREO what did happen here? $XBI biotech is đź’©đź’©đź’©

User Image ScottyDoesntKnowMeSon Posted - 2 days ago

$MREO nothing looks good on this on the technicals heading into this chat

User Image fvazquez Posted - 2 days ago

$MREO anybody has an idea why is this stock dropping 10%?

User Image CEOofstocks Posted - 2 days ago

$MREO never thought the $2 range would be back but it's in sight now. Hopefully timing lines up with $SLS going full send

User Image LDT79 Posted - 2 days ago

$MREO deleted 6 months of gains in 3 days! ww

User Image LDT79 Posted - 2 days ago

$MREO the delay in #Alvelestat could be because management is positive on clinical trial for Bronchiolitis Obliterans Syndrome with completion DEC 1st, 2024 - Alvelestat is worth even more now. This + amended agreement with $AZN might explain many things

User Image cheetohottaki Posted - 2 days ago

$MREO what a nightmare, thanks Denise, and the spineless Ultragenix puppets on the board

User Image polker9 Posted - 2 days ago

$MREO dont want to buy but....going to buy. gift

User Image Governor_Richie Posted - 2 days ago

$MREO We all should have sold at 5 bucks and bought back now.

User Image LDT79 Posted - 2 days ago

$MREO short term noise. P3 might still start by end of year

User Image MJM98 Posted - 2 days ago

$MREO added. Gift from God

User Image CrispDry Posted - 2 days ago

$MREO sold like 80% of my holding and rolled into $RARE

Analyst Ratings
Cantor Fitzgerald Overweight Oct 1, 24
Cantor Fitzgerald Overweight Sep 16, 24
Needham Buy Aug 13, 24
Cantor Fitzgerald Overweight Jul 22, 24
Leerink Partners Outperform Jun 20, 24
Baird Outperform Jun 13, 24
Cantor Fitzgerald Overweight Jun 12, 24
Needham Buy Jun 12, 24
Cantor Fitzgerald Overweight May 16, 24